1. Introduction {#sec1}
===============

According to a 2012 year-end report, cerebrovascular disease is a main cause of death in patients receiving hemodialysis (HD) in Japan \[[@B1]\]. A lower estimated glomerular filtration rate is associated with lower cerebral blood flow \[[@B2]\], and patients with chronic kidney disease or who were receiving HD tend to develop cerebral infarction with high frequency even if they were asymptomatic \[[@B3], [@B4]\]. Therefore, it is important to recognize that patients with renal impairment may have vascular disorders, including ischemic stroke. Regarding the evaluation of vascular disorders, aortic arch calcification (AAC) using chest radiography has been a concern in clinical settings \[[@B5], [@B6]\]. To date, AAC was reportedly associated with cerebral ischemic disorder \[[@B7]\], in addition to cardiovascular disease \[[@B8]\].

Near-infrared spectroscopy (NIRS) has recently been used in various clinical settings to measure the regional saturation of oxygen (rSO~2~), a real-time marker of tissue oxygenation \[[@B9]--[@B14]\]. Cerebral rSO~2~ values were reportedly significantly lower in patients receiving HD than in healthy controls \[[@B15], [@B16]\]. Furthermore, these values were associated with pH, HD duration, serum albumin concentration, and the presence of diabetes mellitus \[[@B16]\]. However, no studies have examined the correlation between cerebral oxygenation and vascular disorders represented by AAC in HD patients. Therefore, here we aimed to clarify the associations between AAC and clinical parameters, including cerebral rSO~2~ values, in patients receiving HD.

2. Materials and Methods {#sec2}
========================

We included patients receiving HD who met the following criteria: (1) with ESRD receiving intermittent HD, (2) AAC grade confirmed by chest radiography, and (3) presence of arteriovenous fistula as vascular access for HD. The exclusion criteria included any uncontrolled patients\' condition: congestive heart failure with pleural effusion, acute cerebrovascular disease, obvious disturbing condition including cognitive impairment, and lung disease with shortness of breath at rest or high concentrated oxygen administration.

One hundred and four patients receiving HD were included (80 men and 24 women; mean age, 67.4 ± 9.6 years; mean HD duration, 4.7 ± 6.7 years). The causes of chronic renal failure were diabetes mellitus (51 patients), chronic glomerulonephritis (23 patients), nephrosclerosis (15 patients), and other (15 patients). Each patient was receiving maintenance HD two or three times a week with each HD session lasting 3 or 4 hours. The patients\' general characteristics are summarized in [Table 1](#tab1){ref-type="table"}. Written informed consent was obtained from all participants and this study was approved by the Institutional Review Board of Saitama Medical Center, Jichi Medical University, Japan (RIN 14--24), and conformed to the provisions of the Declaration of Helsinki (as revised in Tokyo in 2004).

2.1. Data Collection {#sec2.1}
--------------------

### 2.1.1. Patients\' Baseline Characteristics and Clinical Laboratory Measurement {#sec2.1.1}

We collected the patients\' baseline characteristics and other relevant data from their medical charts. The primary disease causing the dialysis requirement as well as any history of ischemic heart disease (IHD), cerebrovascular disease, or smoking, were recorded on the basis of medical records in our hospital.

Blood pressure (BP) and heart rate were measured with patients in the supine position before the HD session at the same time as the cerebral rSO~2~ measurement. Each patient\'s body mass index was calculated as weight (kg) divided by the square of height (m^2^) by each patient\'s dry weight. Blood samples were obtained at ambient temperature from the arteriovenous fistula of each patient prior to HD.

Chest radiography was performed within 1 month of cerebral rSO~2~ measurement, and the AAC grade was determined by two or more radiologists, as recommended in previous reports \[[@B5], [@B6]\]. We then examined the associations between AAC grade and clinical parameters, including cerebral rSO~2~ value, in each patient.

### 2.1.2. Cerebral Oxygenation Monitoring {#sec2.1.2}

Cerebral rSO~2~ was monitored at the forehead using an INVOS 5100C saturation monitor (Covidien Japan, Tokyo, Japan) that utilizes NIRS technology. This instrument uses a light-emitting diode, which transmits near-infrared light at two wavelengths (735 nm and 810 nm), and two silicon photodiodes that act as light detectors to measure oxygenated Hb and deoxygenated Hb. The ratio of oxygenated Hb to total Hb (oxygenated Hb + deoxygenated Hb) signal strength, which is the corresponding percentage, is read as a single numerical value that represents the rSO~2~ \[[@B17], [@B18]\].

All data obtained using this instrument were immediately and automatically stored in sequence. The interobserver variance for this instrument, that is, reproducibility of the rSO~2~ measurement, is acceptable as previously reported \[[@B19]--[@B21]\]. Therefore, cerebral rSO~2~ is considered reliable for estimating the actual cerebral oxygenation. Furthermore, the light paths leading from the emitter to the different detectors share a common part: the 30 mm detector assesses superficial tissue, while the 40 mm detector is used to assess deep tissue. By analyzing the differential signals collected by the different detectors, the current data for cerebral rSO~2~ values were supposed to be obtained in deep tissue 20--30 mm from the body\'s surface \[[@B22], [@B23]\]. These measurements were performed at every 6-second interval during cerebral oxygenation monitoring.

Prior to undergoing HD, the included patients rested in the supine position for at least 10 minutes to reduce the influence of postural change. An rSO~2~ measurement sensor was attached to the patient\'s forehead for measurement in the resting state. Thereafter, rSO~2~ was measured for 5 min before HD, and we evaluated the mean rSO~2~ for 5 min, as a marker of cerebral oxygenation, in each patient.

### 2.1.3. Inclusion of Atherosclerotic Parameters {#sec2.1.3}

In this study, we examined the relationship between cerebral rSO~2~ values and atherosclerotic parameters in addition to the severity of AAC grade, using univariate and multivariate logistic regression analysis. Atherosclerosis/arteriosclerosis was reportedly increased with cardiovascular risk factors, including advanced aging, smoking, hypertension, diabetes mellitus, dyslipidemia, abnormal calcium/phosphate metabolism, and inflammation \[[@B24], [@B25]\]. Therefore, we included several clinical parameters as atherosclerotic parameters in univariate and multivariate logistic regression analysis as follows: age, smoking, systolic and diastolic BP, serum calcium and serum phosphate concentration, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride, blood glucose, hemoglobin A1c, C-reactive protein levels, and severity of AAC grade.

2.2. Statistical Analysis {#sec2.2}
-------------------------

Data are expressed as mean ± standard deviation. An unpaired Student\'s *t*-test was used to compare the two groups. One-way analysis of variance with Tukey\'s test was used to evaluate the significance among the four groups that were divided by AAC grade. A multivariate logistic regression analysis was performed to identify the atherosclerotic factors associated with a cerebral rSO~2~ value less than the mean using stepwise procedure. In this study, the cut-off value for cerebral rSO~2~ was 48.6%. The atherosclerotic parameters with a *p* value of 0.20 in univariate analysis were included in a stepwise manner. All analyses were performed using IBM SPSS Statistics for Windows, version 19.0. Differences with values of *p* \< 0.05 were considered statistically significant.

3. Results {#sec3}
==========

In this study, the mean cerebral rSO~2~ at rest in patients receiving HD was 48.6 ± 9.6%. Patients receiving HD were divided into four groups by AAC grade (from grade 0 to grade 3). There were 23 patients at grade 0, 24 patients at grade 1, 30 patients at grade 2, and 27 patients at grade 3. [Table 1](#tab1){ref-type="table"} shows the patients\' characteristics in each group. Several factors differed significantly among these four groups: age, HD duration, primary disease causing HD requirement, history of IHD, smoking, albumin, and cerebral rSO~2~. In particular, as shown in [Figure 1](#fig1){ref-type="fig"}, cerebral rSO~2~ values decreased as AAC progressed, and these values at AAC grade 3 were significantly lower than those at AAC grades 0 and 1 (AAC grade 0, 53.7 ± 8.3%; grade 1, 50.1 ± 10.1%; grade 2, 48.3 ± 8.6%; grade 3, 43.2 ± 8.8%; AAC grade 3 versus grade 0, *p* \< 0.01; AAC grade 3 versus grade 1, *p* \< 0.05). Furthermore, multivariate logistic regression analysis was performed using the following atherosclerotic parameters: smoking, systolic BP, serum calcium, serum phosphate, low density lipoprotein cholesterol, blood glucose, C-reactive protein, and AAC grades 2 and 3 (*p* \< 0.20 compared with cerebral rSO~2~ values less than mean monitored in this study in univariate analysis). As shown in [Table 2](#tab2){ref-type="table"}, AAC grade 2 (odds ratio \[OR\] = 4.626, 95% confidence interval \[CI\] = 1.241--17.244) and AAC grade 3 (OR = 4.333, 95% CI = 1.134--16.551) in addition to serum phosphate (OR = 3.487, 95% CI = 1.340--9.090) and history of smoking (OR = 4.132, 95% CI = 1.414--12.048) were independently associated with cerebral rSO~2~ values less than the mean in this study.

4. Discussion {#sec4}
=============

Previous reports in nondialysis patients have shown that AAC is related to the presence of diabetes mellitus and renal dysfunction \[[@B5]\] and a strong independent predictor of cardiovascular events, apart from the traditional risk factors \[[@B8]\]. On the other hand, in end-stage renal disease patients, vascular calcification, including AAC, is usually accelerated by mineral and bone disorder \[[@B26], [@B27]\] and associated with cardiovascular and all-cause mortality \[[@B26], [@B28]--[@B30]\]. Therefore, it is important to pay attention to the presence of vascular calcification, which is represented by AAC, in the clinical setting.

However, despite the large number of studies addressing the correlation between AAC and cardiovascular disease, few reports have examined the correlation between AAC and cerebrovascular disorders \[[@B7], [@B31]\]. Using magnetic resonance imaging on ischemic stroke patients not receiving dialysis, AAC was reportedly associated with cerebral small-artery occlusion and white matter disease \[[@B7]\]; therefore, such vascular disorders might directly influence the cerebral circulation. Furthermore, cerebral circulation dysregulation leads to a decrease in regional cerebral blood flow \[[@B32]\] and leukoaraiosis, an indicator of cerebral ischemia with a high prevalence in the anterior circulation of the brain, has also been reported as an independent risk factor for stroke \[[@B33]\] in dialysis patients. In the present study, decreased cerebral rSO~2~ values may have reflected a decreased oxygen supply in the brain via cerebral macro- and/or microcirculation impairments, which may explain the reason why AAC progression was negatively associated with cerebral rSO~2~ value.

The multivariate regression analysis in this study demonstrated that serum phosphate level, history of smoking, and higher AAC grade were independently associated with cerebral rSO~2~. Hyperphosphatemia impairs endothelial function by increasing reactive oxygen species and inhibiting endothelial nitric oxide synthase \[[@B34]\] and contributes to vascular calcification progression \[[@B30]\], which would lead to poor prognosis in patients receiving HD \[[@B35]\]. Thus, cerebral rSO~2~ might be affected by cerebral atherosclerosis progression induced by hyperphosphatemia, although chronic kidney disease -mineral and bone disorder was well-managed in the HD patients in this study. Smoking is a well-known major traditional factor of atherosclerosis. Furthermore, smoking itself reportedly injures endothelial cells \[[@B36], [@B37]\] and accelerates vascular atherosclerotic changes. Thus, this might be why a history of smoking was significantly associated with cerebral oxygenation in this study.

Cerebral rSO~2~ values were significantly associated with the higher AAC grade, which might indicate that vascular disease with AAC decreases cerebral rSO~2~ values. The presence of AAC was associated with arterial stiffness dysregulation \[[@B38]\] and carotid distensibility \[[@B39]\]. Furthermore, arterial stiffness disorders are related to endothelial dysfunction \[[@B40]\] and lead to cerebral circulation dysregulation \[[@B41]\]. Therefore, the presence of AAC might be associated with cerebral microcirculatory impairment via the arterial stiffness disorders, which may have led to the decreased cerebral rSO~2~ in this study.

This study had several limitations. First, the sample size was relatively small and the most of the patients were men. This study was also cross-sectional; therefore, it remains unclear whether the relationships confirmed in this study reflect causes or effects. Furthermore, AAC was only confirmed on the basis of chest radiography in each patient; therefore, elevated vascular calcification might not be accurate compared with other imaging examinations, including computed tomography and magnetic resonance angiography. Therefore, further studies are needed to clarify the associations between vascular calcification, including AAC, and cerebral oxygenation in patients receiving HD.

5. Conclusions {#sec5}
==============

Cerebral rSO~2~ values significantly decreased as AAC progressed. Furthermore, cerebral rSO~2~ value was independently associated with a higher AAC grade in addition to serum phosphate level and history of smoking.
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###### 

Baseline characteristics by AAC grade.

  AAC grade                                   Grade 0      Grade 1       Grade 2      Grade 3
  ------------------------------------------- ------------ ------------- ------------ ----------------
  *N*                                         23           24            30           27
  Sex (men), *n* (%)                          18 (78)      20 (83)       21 (70)      21 (78)
  Age, years                                  64 ± 11      64 ± 10       71 ± 8^c^    70 ± 7
  HD duration, years                          2.6 ± 5.7    5.0 ± 7.6     4.3 ± 7.5    6.7 ± 5.5
  Primary disease, *n* (%)                                                             
   Diabetes mellitus                          11 (48)      7 (29)        20 (70)^c^   13 (48)
   Nephrosclerosis                            2 (9)        4 (17)        4 (12)       5 (19)
   Chronic glomerulonephritis                 8 (34)       8 (33)        4 (12)       3 (11)
   Others                                     2 (9)        5 (21)        2 (6)        6 (22)
  Medical history, *n* (%)                                                             
   Ischemic heart disease                     3 (13)       10 (42)       8 (28)       20 (74)^bd^
   Cerebral infarction                        4 (17)       8 (33)        4 (14)       4 (15)
   Smoking                                    12 (52)      22 (92)^a^    17 (61)      20 (74)
  Body mass index, kg/m^2^                    22 ± 4       23 ± 3        22 ± 3       23 ± 3
  Systolic BP, mmHg                           145 ± 23     139 ± 18      150 ± 20     137 ± 23
  Diastolic BP, mmHg                          79 ± 15      78 ± 13       73 ± 13      69 ± 15
  Pulse pressure, mmHg                        66 ± 16      62 ± 18       77 ± 20^c^   69 ± 14
  Heart rate, per min                         76 ± 11      75 ± 15       71 ± 16      73 ± 12
  Oxygen saturation, %                        96 ± 1       95 ± 2        94 ± 5       95 ± 3
                                                                                      
  Medication, *n* (%)                                                                  
                                                                                      
   RAS blocker (ACEI and/or ARB)              12 (52)      15 (63)       17 (57)      14 (52)
   Calcium channel blocker                    14 (61)      15 (63)       22 (73)      15 (56)
   Beta blocker                               8 (35)       12 (50)       19 (63)      15 (56)
   Vitamin D analog                           11 (48)      10 (42)       13 (43)      11 (41)
   Phosphate binder                           15 (65)      13 (54)       19 (63)      18 (67)
    Calcium-containing phosphate binder       14           10            15           13
    Non-calcium-containing phosphate binder   4            7             10           13
   Cinacalcet                                 1 (4)        1 (4)         3 (10)       4 (15)
   Statin                                     5 (22)       8 (33)        10 (33)      12 (44)
   Antiplatelet agents                        8 (35)       11 (46)       13 (43)      19 (70)
   Erythropoiesis stimulating agent           21 (91)      22 (92)       30 (100)     24 (89)
                                                                                      
  Albumin, g/dL                               3.3 ± 0.6    3.2 ± 0.5     3.1 ± 0.5    2.9 ± 0.6^a^
  Serum sodium, mEq/L                         138 ± 4      137 ± 5       137 ± 3      137 ± 4
  Serum potassium, mEq/L                      4.4 ± 0.8    4.1 ± 0.8     4.2 ± 0.8    4.1 ± 0.5
  Serum calcium, mg/dL                        8.3 ± 0.7    8.9 ± 1.1     8.5 ± 1.1    8.8 ± 0.9
  Serum phosphate, mg/dL                      4.8 ± 1.2    4.4 ± 1.5     4.8 ± 1.3    4.4 ± 1.3
  BUN, mg/dL                                  60 ± 14      55 ± 26       52 ± 20      51 ± 17
  Cr, mg/dL                                   9.1 ± 2.2    8.3 ± 2.2     8.5 ± 2.4    8.2 ± 2.2
  Hb, g/dL                                    9.9 ± 1.3    9.9 ± 1.6     9.4 ± 1.5    9.3 ± 1.5
  Blood glucose, mg/dL                        159 ± 73     149 ± 74      133 ± 37     152 ± 48
  HbA1c, %                                    5.5 ± 1.0    5.5 ± 0.8     5.8 ± 1.0    5.7 ± 0.8
  Total cholesterol, mg/dL                    156 ± 32     148 ± 39      151 ± 40     149 ± 32
  HDL cholesterol, mg/dL                      47 ± 20      43 ± 16       45 ± 14      36 ± 14
  Non-HDL cholesterol, mg/dL                  109 ± 24     107 ± 29      105 ± 36     114 ± 29
  LDL cholesterol, mg/dL                      84 ± 23      77 ± 26       80 ± 31      88 ± 28
  Triglyceride, mg/dL                         96 ± 45      111 ± 33      100 ± 54     117 ± 57
  C-reactive protein, mg/dL                   0.7 ± 1.4    3.4 ± 8.8     1.2 ± 1.6    3.2 ± 4.9
                                                                                      
  Cerebral rSO~2~ value, %                    53.7 ± 8.3   50.1 ± 10.1   48.3 ± 8.6   43.2 ± 8.8^bc^

AAC, aortic arch calcification; HD, hemodialysis; BP, blood pressure; RAS, renin-angiotensin system; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BUN, blood urea nitrogen; Cr, creatinine; Hb, hemoglobin; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; rSO~2~, regional saturation of oxygen. ^a^Significant versus the AAC grade 0 group (*p* \< 0.05). ^b^Significant versus the AAC grade 0 group (*p* \< 0.01). ^c^Significant versus the AAC grade 1 group (*p* \< 0.05). ^d^Significant versus the AAC grade 2 group (*p* \< 0.01).

###### 

Multivariate regression analysis for cerebral rSO~2~ value.

                               Univariate analysis     *p* value   Multivariate analysis   *p* value
  ---------------------------- ----------------------- ----------- ----------------------- -----------
  Age                          1.095 (0.503--2.386)    0.819                               
  Smoking (yes versus no)      2.488 (1.037--5.952)    0.039       4.132 (1.414--12.048)   0.009
  Systolic BP                  2.013 (0.922--4.394)    0.078       ---                     0.083
  Diastolic BP                 1.467 (0.677--3.178)    0.330                               
  Serum calcium                0.576 (0.264--1.255)    0.164       ---                     0.801
  Serum phosphate              2.779 (1.256--6.149)    0.011       3.487 (1.34--9.090)     0.010
  HDL cholesterol              1.535 (0.684--3.444)    0.298                               
  LDL cholesterol              0.433 (0.192--0.977)    0.042       ---                     0.148
  Triglyceride                 0.690 (0.308--1.546)    0.367                               
  Blood glucose                0.440 (0.198--0.980)    0.043       ---                     0.072
  HbA1c                        0.670 (0.292--1.534)    0.342                               
  C-reactive protein           0.369 (0.143--0.952)    0.036       ---                     0.390
  AAC grade (versus grade 0)                                                               
   Grade 1                     1.338 (0.4111--4.366)   0.627                               
   Grade 2                     2.141 (0.700--6.535)    0.179       4.626 (1.241--17.244)   0.023
   Grade 3                     4.444 (1.353--14.705)   0.012       4.333 (1.134--16.551)   0.032

BP, blood pressure; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; rSO~2~, regional saturation of oxygen; AAC, aortic arch calcification; CI, confidence interval.
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